Adline Chem Lab Ltd
Incorporated in 1988, Adline Chem Lab Ltd trades in pharmaceutical formulations, Nutraceutical, and Dietary products.[1]
- Market Cap ₹ 4.45 Cr.
- Current Price ₹ 7.60
- High / Low ₹ 22.2 / 7.60
- Stock P/E
- Book Value ₹ -2.75
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 29.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.45 | 15.36 | 16.94 | 17.18 | 8.10 | 5.59 | 6.59 | 6.33 | 0.74 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 12.43 | 14.42 | 16.50 | 15.97 | 7.23 | 5.01 | 9.91 | 6.56 | 1.04 | 0.80 | 0.18 | 0.30 | 0.24 | |
| Operating Profit | 1.02 | 0.94 | 0.44 | 1.21 | 0.87 | 0.58 | -3.32 | -0.23 | -0.30 | -0.80 | -0.18 | -0.30 | -0.24 |
| OPM % | 7.58% | 6.12% | 2.60% | 7.04% | 10.74% | 10.38% | -50.38% | -3.63% | -40.54% | ||||
| 0.02 | 0.08 | 0.10 | 0.08 | 0.21 | 0.25 | 0.26 | 0.00 | 1.33 | -3.35 | 0.00 | 0.25 | 0.25 | |
| Interest | 0.57 | 0.48 | 0.44 | 0.32 | 0.34 | 0.07 | 0.02 | 0.03 | 0.01 | 0.00 | 0.12 | 0.16 | 0.12 |
| Depreciation | 0.46 | 0.51 | 0.09 | 0.96 | 0.73 | 0.73 | 0.42 | 1.02 | 0.35 | 0.09 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 | -3.50 | -1.28 | 0.67 | -4.24 | -0.30 | -0.21 | -0.11 |
| Tax % | 0.00% | 33.33% | 100.00% | 0.00% | 100.00% | 0.00% | 7.43% | 0.00% | -7.46% | 0.00% | -10.00% | -33.33% | |
| 0.01 | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | -3.76 | -1.28 | 0.72 | -4.23 | -0.27 | -0.13 | -0.03 | |
| EPS in Rs | 0.02 | 0.03 | 0.02 | 0.02 | 0.00 | 0.05 | -6.43 | -2.19 | 1.23 | -7.23 | -0.46 | -0.22 | -0.06 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 19% |
| TTM: | 89% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 0% |
| 1 Year: | -64% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 |
| Reserves | 1.21 | 1.21 | 1.21 | 1.19 | 1.18 | 1.18 | -2.64 | -3.92 | -3.20 | -7.42 | -7.22 | -7.34 | -7.46 |
| 6.69 | 9.25 | 9.01 | 9.94 | 11.32 | 5.35 | 2.85 | 2.50 | 1.32 | 1.33 | 1.36 | 1.49 | 1.65 | |
| 2.77 | 2.32 | 2.34 | 3.97 | 5.01 | 9.46 | 1.52 | 1.20 | 0.91 | 0.31 | 0.06 | 0.08 | 0.08 | |
| Total Liabilities | 16.52 | 18.63 | 18.41 | 20.95 | 23.36 | 21.84 | 7.58 | 5.63 | 4.88 | 0.07 | 0.05 | 0.08 | 0.12 |
| 8.17 | 10.08 | 10.27 | 12.68 | 12.45 | 11.99 | 4.78 | 3.64 | 4.43 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.20 | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 8.15 | 8.35 | 7.94 | 8.27 | 10.91 | 9.85 | 2.80 | 1.99 | 0.45 | 0.07 | 0.05 | 0.08 | 0.12 | |
| Total Assets | 16.52 | 18.63 | 18.41 | 20.95 | 23.36 | 21.84 | 7.58 | 5.63 | 4.88 | 0.07 | 0.05 | 0.08 | 0.12 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.31 | 0.39 | 0.83 | 2.46 | 0.89 | -0.95 | -11.34 | -0.29 | 0.21 | 0.01 | -0.17 | -0.23 | |
| -1.04 | -2.44 | -0.21 | -3.18 | -0.37 | -0.28 | 11.24 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | |
| -0.09 | 2.18 | -0.78 | 0.63 | 1.04 | -0.29 | -0.02 | -0.03 | -0.01 | 0.00 | 0.15 | 0.25 | |
| Net Cash Flow | 0.18 | 0.12 | -0.15 | -0.09 | 1.56 | -1.51 | -0.12 | -0.21 | 0.20 | 0.01 | -0.02 | 0.02 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 53.46 | 57.74 | 53.87 | 56.30 | 102.74 | 135.81 | 79.20 | 91.11 | 34.53 | |||
| Inventory Days | 109.25 | 77.67 | 46.15 | 55.54 | 181.31 | 832.82 | 81.53 | 46.98 | 197.71 | 0.00 | ||
| Days Payable | 45.42 | 43.12 | 41.39 | 49.24 | 63.34 | 436.97 | 41.89 | 28.91 | 342.19 | |||
| Cash Conversion Cycle | 117.30 | 92.30 | 58.62 | 62.60 | 220.71 | 531.66 | 118.84 | 109.18 | -109.95 | |||
| Working Capital Days | 47.76 | 24.71 | -6.46 | -29.53 | -139.69 | -317.99 | -72.00 | -66.89 | -764.53 | |||
| ROCE % | 4.29% | 3.39% | 2.84% | 2.00% | 1.98% | 0.59% | -40.35% | -23.83% | -10.95% | 5.90% |
Documents
Announcements
-
Intimation Of Receipt Of Approval For Reclassification Application Of Promoter Under Regulation 31A Of SEBI (LODR) Regulations, 2015.
26 Nov - BSE approved promoter-to-public reclassification on 25 Nov 2025 for 219,800 shares (~3.75%).
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Newspaper Publication for Financial Results of the Company for the quarter and half year ended 30th September, 2025.
-
Announcement under Regulation 30 (LODR)-Resignation of Chairman and Managing Director
12 Nov - MD Sarang Pathak and Promoter Director Hemant Parikh resigned effective Nov 12, 2025; committees reconstituted Nov 13.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
12 Nov - MD Sarang Pathak and promoter director Hemant Parikh resigned effective Nov 12, 2025; committees reconstituted Nov 13.
- Unaudited Standalone Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September, 2025 12 Nov
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ACLL is in the business of manufacturing pharmaceutical chemicals, fine chemicals,
and agrochemical products.